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Catheter ablation of atrial ﬁbrillation (AF) is a highly effective therapy to achieve freedom
of recurrent arrhythmia and relief from symptomatic AF. Transmural ablation of atrial
tissue is crucial for success. Thus steerable sheaths and catheter design with contact
measurement as an additional feature have been developed to increase success rates. New
3 dimentional (3D) mapping technologies engage clinical routine to reduce ﬂuoroscopy
time and radiation dose for patients and medical staff to a minimum. To unmask dormant
pulmonary vein reconduction and to avoid early pulmonary vein reconduction adminis-
tration of adenosine is useful. Future approaches aim at individualized ablation strategies
taking clinical and electrophysiologic characteristics of the individual patient into account.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Atrial ﬁbrillation (AF) is associated with an increased risk for
thromboembolic events, hospitalization and mortality. The
number of patients suffering from AF steadily increases, as
patients get older and present with more comorbidities and
structural heart diseases [1]. Treatment for AF has constantly
evolved over the last decade. Catheter ablation has become a
routine procedure, with excellent success rates accompanied
by acceptable complication rates. Still careful patient selection
is important for clinical success. Since superiority of catheter
ablation against medical, antiarrhythmic treatment, avoiding
recurrence of AF, is shown, ESC guidelines admit, that catheter
ablation could be performed as a ﬁrst line therapy for patients
suffering from AF [2,3], which was consolidated by the
MANTRA-PAF trial published in October 2012. This rando-
mized comparison of ﬁrst line catheter ablation in paroxysmal
AF to antiarrhythmic drug therapy showed signiﬁcantly more
patients free from AF and symptomatic AF and better quality
of life in the ablation group at the 24 month of follow up. AF
burden though did not differ [4]. Therefore the 2012 expert
consensus statement from the Heart Rhythm Society, Eur-
opean Heart Rhythm Association and European Cardiac
Arrhythmia Society on catheter and surgical ablation of atrial
ﬁbrillation includes ablation, if performed by an electrophy-
siologist, who has received appropriate training in an experi-
enced center, as a reasonable ﬁrst-line therapy for preselected
patients suffering from paroxysmal AF [5].Mechanisms of AF
Mechanisms causing paroxysmal AF appear to be different
from those causing persistent AF. Paroxysmal AF is deﬁned
by spontaneous termination and episodes shorter than 7
days. Persistent AF does not self-terminate and episodes last
longer than 7 days. Haissaguerre ﬁrst described focal triggers
within the atrial muscular extensions of pulmonary veins [6].
High frequency electrical activity of these focal sources is
crucial for initiating paroxysmal AF in 85–95% of patients.
Knowing that has led to the development of effective ablation
strategies to isolate pulmonary veins electrically. Circumfer-
ential, antral pulmonary vein isolation became a therapy of
choice in patients suffering from paroxysmal AF [7]. Cumu-
lative success rates, between 80% and 90%, after more than
one procedure, are reported in the literature [3]. Main cause of
recurrent arrhythmias in these cases is attributed to electrical
reconnection of former isolated pulmonary veins [8]. In
persistent AF mechanisms are multiple and therefore abla-
tion strategies to ablate suffer from imperfection. Structural
and electrical alterations in the atrial myocardium are
accused of perpetuating AF. Coexisting hypertension, valvular
disease and heart failure lead to abnormal atrial pressure,
causing wall stress and regional ﬁbrosis, which provides
substrate for persistent AF [9]. Atrial rotors, focal driver
and wandering wave fronts seem to play a decisive role
in perpetuation of AF [10]. Patients with persistent AF
have distinctively reduced success-rates. Up to 30% of this
population develops recurrent AF over time [11]. During thelong-term follow-up (5 years) only 29% of patients stayed free
of any arrhythmia after a single procedure. Most recurrences
occurred within the ﬁrst 6 months after initial procedure.
Additional procedures can raise long-term success to 63% at
5 years [12]. Another signiﬁcant mechanism for recurrence, as a
result of post-ablation modulation, is macro-reentry tachycar-
dia, which accounts for about a third of recurrences after atrial
defragmentation [13]. Creation of trans mural scars therefore
represents a crucial endpoint in ablation of atrial ﬁbrillation
and bears a challenge for operator and technical equipment.
Thus there is a constant development of procedure strategies
and technical support to reach these endpoints.Catheter tissue contact
Catheter tissue contact is crucial for radiofrequency lesion
size and depth. Contact force (CF) 420 g applied to the atrial
endocardium during AF ablation, correlates with better clin-
ical outcome at the 12 month in AF ablation compared to less
than 10 g [14]. Recently published data conﬁrmed that there is
signiﬁcant difference in CF at different anatomical sites
during pulmonary vein isolation (PVI) [15]. It could be shown,
that the lowest contact force at the left pulmonary veins was
applied to the carina anteriorly. At the right pulmonary veins
lowest CF was to the carina. These segments correlate with
usual regions of early electrical reconduction [16]. Knowledge
about this may improve clinical outcomes during PVI.
A notable improvement of stability and catheter contact to
the atrium is provided by the use of steerable sheaths. Several
clinical studies have proven the concept of better tissue
contact achieved by steerable sheaths, that results in higher
success rates without increasing complication rates. There is
a signiﬁcant reduction in ﬂuoroscopy time, while procedure
time is not prolonged due to the use of steerable sheaths [17–
19]. As mentioned above, on the one hand sufﬁcient catheter–
tissue contact is crucial for pulmonary vein isolation, on the
other hand data about amount and vector of force delivered to
the tissue is important information in order to avoid throm-
boembolic events and perforation through the atrial wall. In
general, it is difﬁcult for operators to exclusively deﬁne a
sufﬁcient catheter–tissue contact by tactile feedback; up to
now ﬂuoroscopy and signal-quality have been additionally
used to conﬁrm proper touch to atrial surface, both of which
are implicit variables deﬁning adequate tissue contact. To
generate reliable information about delivered pressure to
atrial wall, ablation-catheters with different features of con-
tact measurement or feedback have been developed and
investigated in the past. Currently there are two different
technologies to measure contact force via an ablation cathe-
ter. Specially designed catheters, with integrated force sensors
in the tip have been developed. The Tacti-Caths (Endosense,
Switzerland) System contains a pressure measurement based
on a ﬁber-optic sensor technology with a sensitivity of less
than 1 g. Another, quite similar system is represented by the
SMART Touch™ Technology (Biosense Webster), which uses a
mechanical catheter tip to provide valid data of pressure to
the atrial endocardium, expressed in grams. Published data
support the thesis that complications due to excessive
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ablation of atrial ﬁbrillation [20]. Recently it has been shown
that contact force correlates with better clinical outcome of
patients after pulmonary vein isolation. Best results are
achieved when ablation lesions are placed with an average
contact force above 20 g. Complete clinical failure is reported
when contact force during ablation does not exceed an
average of 10 g [14]. Using contact force measurements can
signiﬁcantly reduce ablation and procedure time and can
reduce acute pulmonary vein reconnection from 36% to 12%
of patients [21]. A new method of impedance based contact
measurement uses a very different approach to conﬁrm tissue
contact. The Ensite-Contacts-System (St. Jude medical, St.
Paul MN), measures local impedance at the border between
electrode and tissue and expresses a so-called electrical
coupling index (ECI) [22]. ECI correlates to lesion-size and
gives information about catheter–tissue contact. A decisive
advantage of the Ensite-Contacts-System is that contact
information is independent from catheter-orientation and
tissue-type (smooth or trabecular atrial endocardium). Infor-
mation about lesion formation, during ablation, is displayed
by impedance drop. Discrimination of scar tissue from
healthy atrial tissue is another advantage of this technology.
As measurement of CF can improve outcome and safety it is
important to mention that CF is still an indirect surrogate
parameter of transmurality and quality of lesions. Visualiza-
tion of lesion formation and extent would improve perfor-
mance in ablation of AF. Maybe real time magnetic resonance
imaging could be the answer to this question in the future.Validation of lesions
Commonly circumferential antral PVI is performed using the
electro-anatomical 3 dimensional (3D) mapping and double
transseptal puncture (TSP) technique. Using this approach a
decapolar circumferential catheter and an ablation catheter
are advanced through the interatrial septum to the left
atrium. By stimulating from the circumferential catheter,
which is positioned in the pulmonary vein, exit block can
be conﬁrmed or excluded. By stimulation from the coronary
sinus catheter entrance block can be proven or a present gap
can be unmasked by the earliest signal at the circumferential
catheter. As mentioned above, two separate TSP are required
for this concept. In some cases, it might be difﬁcult to
perform a second TSP (e.g. very small atriums or in redo-
procedures with scarred interatrial septum). Sometimes it is
just the operator's favor only to perform single TSP to
increase latitude within the left atrium. In these cases the
so-called “Pace and Ablate” strategy has been described as a
useful tool to ﬁnd gaps along ablation lines or to proof
competent lesions. In a prospective single-center study this
concept was investigated [23]. Initially linear lesions were
established around both ipsilateral veins. Thereafter the lines
were followed in sinus rhythm by the ablation-catheter to
detect residual sharp and fragmented potentials, represent-
ing electrical gaps along the lines. These spots with main-
taining signal have been ablated immediately until just far
ﬁeld electrograms were seen. Further on, the ablation lines
were tested again during high output pacing by followingthem with the ablation catheter. Unexcitable lines were
considered as trans mural. So capture of the atrium did
unmask excitable gaps, which needed further ablation-
treatment. There was no sharp electrogram detected in sinus
rhythm at these regions. By this strategy the ablation lines
around pulmonary veins can be tested for block by the single
catheter approach. In the same manner, any other ablation
line can be validated. This “pace and ablate” technique
provides a simple and reproducible way to achieve clear
endpoints. Bidirectional conduction block was seen in 95%
of patients and long-term success rate with 84% free of any
atrial tachycardia has been achieved in this prospective
single-center study during a 12 month follow-up.Avoiding early pulmonary vein reconnection
Recurrence of AF in patients after successful PVI is still a
major problem and often requiring more than one procedure
to achieve suppression of AF [24]. Predominantly this recur-
rence is due to recovered electric conduction to the left
atrium of primary isolated pulmonary veins [25,26]. Mostly
this is the result of insufﬁcient ablated (not trans mural
ablated) tissue. About 30% of reconnection occurs within
30–60 min waiting time after complete isolation of pulmonary
veins. Predominant regions in the left atrium are on the left
side at the intravenous ridge and the ridge between upper
pulmonary vein and left atrial appendage. On the right side
usually the roof and the ﬂoor of the right pulmonary veins
develop early reconnection [16,27]. That may be due to low
catheter contact force to these anatomical regions. When
entrance- and exit-block is achieved there is still the possi-
bility of dormant pulmonary vein conduction, which can be
unmasked by administration of adenosine. Positive adeno-
sine response predicts spontaneous reconduction of dormant
pulmonary veins after 30–60 min waiting time [28]. Investi-
gating waiting time and adenosine-challenge in a cohort of 75
patients with paroxysmal AF, Yamane and colleagues
demonstrated freedom of AF in 92% of patients during a
mean follow-up of 370 days [29]. Therefore in general a
waiting time of at least 30 min and testing with adenosine
is an additional tool to ensure PVI in selected cases.3D-mapping
In interventional cardiology, conventional ﬂuoroscopy is still
the leading imaging technology. The most signiﬁcant advan-
tage for the operator, using this technology, is that catheters
are displayed in real time. Fluoroscopy in different angels is
used to ensure correct positioning of catheter tips. While
providing a two dimensional orientation, especially in AF
procedures, ﬂuoroscopy is associated with a signiﬁcant
amount of X-ray exposure to patient and physician [30,31].
For better orientation and reduction of X-ray exposure and
ﬂuoroscopy time 3D-mapping technologies have been imple-
mented and are routinely used today [32]. Today two differ-
ent electroanatomic mapping systems are widely used in
clinical practice. The CARTO mapping system (CARTO-3),
which relies both on a magnet-based visualization of ablation
Fig. 1 – Left anterior oblique view of a prerecorded cine loop,
showing the coronary sinus catheter (B, yellow tip) and a
right ventricular apex catheter (A, blue tip). Decapolar ring
catheter (C) is introduced through a long, steerable sheath
and placed at the ostium of the left inferior pulmonary vein:
brown. Left superior pulmonary vein: blue, right superior
pulmonary vein: green, and right inferior pulmonary vein:
red. Esophageal temperature-probe (D). Outer limits of the
left atrium are marked with dotted lines.
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both tip and catheter curve visualization and simultaneous
visualization of multiple electrodes. The second electroana-
tomic mapping system is guided by electrical impedance
mapping (NavX, St. Jude medical, St. Paul MN) using voltage
and impedance for localization. Both of them have demon-
strated reduction in ﬂuoroscopy duration [32,33]. A small case
series is published with 20 patients undergoing AF ablation
using zero ﬂuoroscopy with NAVX Ensite System (St. Jude
medical, St. Paul MN) which speaks for the accuracy of
electroanatomical mapping nowadays [34]. Another techni-
que is intracardiac echocardiography (ICE), which signiﬁ-
cantly reduces ﬂuoroscopy time and time spent in left
atrium compared to preprocedural magnetic resonance ima-
ging (MRI) [35]. There is also a safety advantage about using
this technique to guide transeptal puncture and titrate energy
delivery, to recognize complications like pericardial effusion,
pulmonary vein stenosis at an early stage [36]. To keep the
X-ray exposure low and still have the familiar view of
ﬂuoroscopy, a new 3D catheter mapping technology, which
allows real time device tracking in prerecorded, conventional
ﬂuoroscopy cine loops, was recently implemented. The
guided medical positioning system (St. Jude medical, St. Paul
MN) is constructed from three components: (I) an electro-
magnetic reference sensor (patient reference sensor, PRS),
which is placed at the patient's upper end of the sternum like
a conventional adhesive ECG electrode, (II) multiple trans-
mitters, which generate a set of alternating low intensity
electromagnetic ﬁelds (o200 μT) and (III) passive single coil
sensors (o1 mm3), which can be incorporated to different
kinds of intracardiac devices, like electrophysiology-cathe-
ters, steering sheaths, pacemaker leads or coronary guide-
wires [37]. This system has a quantitative accuracy of less
than 0.5 mm positional error and less than 11 orientation
error, allowing precise navigation inside the heart. It con-
tinuously receives and processes information from signal
sources and real time ECG. By that, cardiac and respiratory
motion is compensated and the sensor-equipped devices can
be displayed to prerecord, ECG-synchronized ﬂuoroscopy cine
loops (e.g. in left oblique and right oblique view), with a
latency of 80 ms, which is due to capture and computation of
signals. (Fig. 1) With this technology a reduction of 50%
ﬂuoroscopy time for AF ablation, from 31 min to 16 min, has
been achieved [38]. By using a sensor equipped, irrigated tip
ablation catheter, also displayed by the same technology, a
further reduction in ﬂuoroscopy time has been achieved to
less than 2 min, in the primary experience of AF ablation [39].Individualized ablation strategies
Circumferential PVI has become a standard therapy for parox-
ysmal AF. Currently, patients with paroxysmal AF are
approached by wide antral PVI to avoid pulmonary vein steno-
sis. Commonly irrigated radiofrequency ablation and point-by-
point strategy is used nowadays. Three dimensional mapping
systems are in clinical use to display anatomy of an imported
computer tomography, to ease navigation and reduce X-ray
dose. Satisfactory results are shown in a long-term 5-year
follow-up of patients after AF ablation of paroxysmal AF. Sinusrhythm was present in 79% after one or more ablations. Also in
this study 94% recurrent AF was due to recovered electrical
reconnection of pulmonary veins [40].
For patients with persistent AF the optimal ablation approach
remains uncertain. Success rates of AF ablation in patients with
persistent AF are signiﬁcantly lower than in paroxysmal AF; 20%
single procedure success and 72% multiple procedure success
during a 5-year follow-up were free of AF [41]. Ablation strategies
therefore have become more extensive in patients with persis-
tent AF, including ablation of complex fractionated atrial elec-
trograms (CFAE), linear ablation (Fig. 2), ablation inside coronary
sinus superior vena cava and autonomic ganglia. Willems and
colleagues nicely demonstrated in a prospective randomized
comparison that additional roof and mitral isthmus line
signiﬁcantly decreases AF recurrence in patients with persistent
AF [42]. Creation of linear lesions across the left atrial roof or
between the left inferior pulmonary vein and the mitral annulus
is a common way to address left atrial substrate. To achieve
complete block in linear lesions can be difﬁcult, is time con-
suming and might promote left atrial macro-reentry tachycardia
[43]. Recent data support the thesis, that additional lines and
defragmentation in the left atrium does not improve success
rate in persistent AF [44].
Another substrate for AF perpetuation could be repre-
sented by CFAEs. These rapid electrograms with multiple
split components can be located both in the left and right
atrium. Predominantly they are located at the interatrial
septum (83%), around the pulmonary veins (67%), the left
atrial roof (61%), the proximal CS (59%), the cavotricuspid
isthmus (31%) and the mitral annulus (24%). Rarely, they are
found at the infero-lateral aspect of the right atrium (7%) and
the superior vena cava (4%). Ablation of CFAEs can terminate
AF during ablation procedure without external cardioversion
[45]. CFAEs may represent pivot points or rotors where
excitation turns around and creates reentry to maintain AF
Fig. 2 – Two electroanatomical maps of patients with persistent AF. (A) PA view of a left atrium showing successful PVI. This
voltage map shows healthy endocardium (voltage 40.5 mV). Scar is depicted in gray (o0.2 mV). (B) AP view of a left atrium
showing extensive septal substrate, which was defragmented by a lower septal line (black triangle), high septal line (white
triangle) and a roof-line (white arrow). LSPV: left superior pulmonary vein; LIPV: left inferior pulmonary vein; RSPV: right
superior pulmonary vein; RIPV: right superior pulmonary vein; LAA: left atrial appendage; and CS: coronary sinus.
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ablation versus CFAE ablation in a cohort of patients with
persistent AF, showed no difference in freedom of atrial
tachyarrhythmias after one ablation. Though recurrence of
persistent AF was more frequent in the linear lesion group,
the group with ablation of CFAEs showed more recurrence
due to atrial tachycardia. Freedom of any atrial tachyarrhyth-
mia and re-ablation were almost the same in both groups
[47]. Following the thesis of CFAE ablation has recently been
investigated in the CONFIRM trial. Focal impulse and rotors
modulation (FIRM) plus conventional ablation (FIRM-group)
was tested against conventional ablation alone (FIRM-
blinded-group). The primary endpoint (AF termination or
consistent slowing) was achieved in 86% of FIRM guided
procedures versus 20% of FIRM-blinded procedures. After a
single procedure freedom of AF was achieved 82.4% in the
FIRM-group versus 44.9% in the FIRM-blinded-group, which is
statistically superior outcome for the FIRM group after a
mean follow-up of 273 days [48]. Further studies are needed
to investigate this new concept and to compare long-term
follow-up with actual long-term results.
On the other hand the Bordeaux group around Michel
Haissaguerre and Pierre Jais recently challenged the concept
of CFAE ablation. Using high density mapping (4400 points) in
the left atrium, they elaborated that distribution of CFAEs is
highly rhythm dependent [49]. Fractionated electrograms during
sinus rhythm or coronary sinus pacing mostly result from wave
collisions. Thus targeting these sites during sinus rhythm does
not seem to be more speciﬁc to identify arrhythmogenic sub-
strate. Therefore current strategies in CFAE ablation seem to
target atrial myocardium with normal voltage and at least no
scar tissue. Most of the sites with CFAEs seem to correspond to
areas of wave-collision and these regions play a minor role in
perpetuating atrial ﬁbrillation. Quite commonly it is seen that
patients suffering from persistent AF show normal voltage
(41.0 mV) in the left atrium during mapping in sinus rhythm
and do not show any scar area. So the question is raised whether
additional lines and ablation of fragmented atrial electrograms in
every patient with persistent AF is helpful. Instead of resting only
on patient's AF history, an individualized ablation approachmight be helpful to make a decision regarding the ablation line
concept, taking into account the underlying substrate. Ablation
of normal voltage tissue may just facilitate proarrhythmic
substrate for left atrial macroreentry tachycardia. As we know
from clinical practice those patients, who suffer from this kind of
tachycardia, are highly symptomatic [50]. A new non-invasive
electrocardiographic mapping system consisting of recording
body surface electrograms from a 252-electrode-vest placed on
the torso combined with CT-scan-based biatrial anatomy (Car-
dioInsight Inc., USA), to deﬁne ablation-strategy in patients with
atrial tachycardia was recently published [51]. If this system is
applicable to patients with atrial ﬁbrillation, it might be possible
to individualize ablation-strategies and improve outcome.
So up to now there is still no clear concept in addressing
persistent AF with additional ablation strategies. Further studies
are on their way to address these issues in the ablation of AF.Complications
Catheter ablation of atrial ﬁbrillation is undoubtedly one of
the most complex procedures in cardiac electrophysiology.
The risk of suffering from any complication is therefore
higher in atrial ﬁbrillation than in ablation of any other
arrhythmia. Necessity of transeptal approach, intracardiac
catheter manipulation and ablation on delicate structures
like left atrial wall, implicate about 4.54% major complica-
tions in total. Incidence of cardiac tamponade in a Worldwide
Survey of AF ablation reports 1.31%. Caridac tamponade is,
with 25%, the most frequent cause of periprocedural death,
which itself has an incidence of 0.15% [24,52]. The potential
risk of delayed cardiac tamponade (41 h post ablation) is
always to be taken into account by taking care of these
patients. Vascular complications, like pseudoaneurysms and
ateriovenous ﬁstulae occurring in about 1.5%, are due to size
and number of venous sheaths and can lead to increased
morbidity and additional therapy [24]. Stroke is another
severe complication of AF ablation, which could either be
caused by thrombo-embolism or air embolism. While the
literature reports between 0% and 7% for thromboembolism,
Table 1 – Major complications.






Phrenic nerve palsy 0.17
Death 0.15
a PV-Stenosis, pulmonary vein stenosis, needed intervention.
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about 1%; the incidence for silent microemboli is about 17%
[24,53]. Up till now the impact on neurological and neurocog-
nitive function of these microemboli is not clear and is a
matter of ongoing research. Pulmonary vein stenosis became
a rare complication (1.3%), because of wide area catheter
ablation in AF and needs intervention in 0.3–0.6% of all cases
[24,54]. Persistent phrenic nerve palsy occurs in 0.17% and
can be avoided by high output pacing, especially when
ablation is performed in the area around the right superior
pulmonary vein and the vena cava superior [5]. Because of an
extremely high mortality of 80% the left atrial esophageal
ﬁstula, which is occurring less than 0.1–0.25% of cases, is a
complication which should be avoided by any means [5,24].
Patients should be informed about the delayed onset of
symptoms (2–4 weeks) and should be cautious about taking
proton-pump inhibitors for about 3 weeks following ablation.
So it is clear to say, that patient selection and inform
consent are to be taken very seriously, because of the
potential risk of severe complications, even if the incidence
is acceptably low (Table 1).Conclusion
Catheter ablation in patients with symptomatic AF is now at
the forefront of the treatment algorithm and has lead to a
signiﬁcant improvement in quality of life. Complication rates
are low but could be severe and life threatening. Well-trained
physicians should perform catheter ablation of atrial ﬁbrillation
in experienced centers only. Success rates in patients suffering
from paroxysmal AF are around 80%, even though more than
one procedure is needed. The role of catheter ablation in
patients with persistent AF is less clear. Constant effort to
understand mechanisms of persistent AF is done, to develop
new therapeutical strategies to face this clinical presentation.Conﬂict of interest
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